This research and development collaboration will combine Gubra’s parathyroid hormone (PTH) analogue, developed using the company’s streaMLine peptide discovery platform, with Camurus’ FluidCrystal drug delivery technology to enable extended, patient-friendly dosing, the company states.

“Given the encouraging early development data, we look forward to this collaboration, combining Gubra’s strengths in drug discovery and preclinical expertise with Camurus’ FluidCrystal technology, late-stage development and commercialization capabilities. The partnership aligns with our focus on endocrine and rare diseases and shared goal of creating innovative therapies for patients with unmet needs”, says Markus Johnsson, Senior Vice President R&D, Camurus.

“We are pleased to initiate this collaboration with Camurus. By combining our PTH analogue with Camurus’ FluidCrystal technology, we see a strong foundation for developing a long-acting treatment that can improve patient quality of life through reduced injection frequency and more stable disease control. We look forward to joining forces with Camurus to advance this promising opportunity”, says Louise S. Dalbøge, Chief Science Officer, Gubra.

Under the terms of the agreement, Camurus will develop and commercialize the product and Gubra has the option to co-finance the product through development. Gubra will receive tiered royalties scaled to its chosen level of financial participation.